Skip to main content
Erschienen in: CNS Drugs 9/2010

01.09.2010 | Review Article

The Association between Conventional Antidepressants and the Metabolic Syndrome

A Review of the Evidence and Clinical Implications

verfasst von: Dr Roger S. McIntyre, Ka Young Park, Candy W. Y. Law, Farah Sultan, Amanda Adams, Maria Teresa Lourenco, Aaron K. S. Lo, Joanna K. Soczynska, Hanna Woldeyohannes, Mohammad Alsuwaidan, Jinju Yoon, Sidney H. Kennedy

Erschienen in: CNS Drugs | Ausgabe 9/2010

Einloggen, um Zugang zu erhalten

Abstract

Major depressive disorder is a prevalent recurrent medical syndrome associated with inter-episodic dysfunction. The metabolic syndrome is comprised of several established risk factors for cardiovascular disease (i.e. abdominal obesity, dyslipidaemia, dysglycaemia and hypertension). The criterion items of the metabolic syndrome collectively represent a multi-dimensional risk factor for cardiovascular disease and type 2 diabetes mellitus. Extant evidence indicates that both major depressive disorder and the metabolic syndrome, albeit distinct, often co-occur and are possibly subserved by overlapping pathophysiology and causative mechanisms. Conventional antidepressants exert variable effects on constituent elements of the metabolic syndrome, inviting the need for careful consideration prior to treatment selection and sequencing. Initiating and maintaining antidepressant therapy should include routine surveillance for clinical and/or biochemical evidence suggestive of the metabolic syndrome.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002 Jan 16; 287(3): 356–9PubMedCrossRef Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002 Jan 16; 287(3): 356–9PubMedCrossRef
2.
Zurück zum Zitat Gans RO. The metabolic syndrome, depression, and cardiovascular disease: interrelated conditions that share pathophysiologic mechanisms. Med Clin North Am 2006 Jul; 90(4): 573–91PubMedCrossRef Gans RO. The metabolic syndrome, depression, and cardiovascular disease: interrelated conditions that share pathophysiologic mechanisms. Med Clin North Am 2006 Jul; 90(4): 573–91PubMedCrossRef
3.
Zurück zum Zitat McIntyre RS, Rasgon NL, Kemp DE, et al. Metabolic syndrome and major depressive disorder: co-occurrence and pathophysiologic overlap. Curr Diab Rep 2009 Feb; 9(1): 51–9PubMedCrossRef McIntyre RS, Rasgon NL, Kemp DE, et al. Metabolic syndrome and major depressive disorder: co-occurrence and pathophysiologic overlap. Curr Diab Rep 2009 Feb; 9(1): 51–9PubMedCrossRef
4.
5.
Zurück zum Zitat Anderson RJ, Freedland KE, Clouse RE, et al. The prevalence of comorbid depression in adults with diabetes: a meta-analysis. Diabetes Care 2001 Jun; 24(6): 1069–78PubMedCrossRef Anderson RJ, Freedland KE, Clouse RE, et al. The prevalence of comorbid depression in adults with diabetes: a meta-analysis. Diabetes Care 2001 Jun; 24(6): 1069–78PubMedCrossRef
6.
Zurück zum Zitat Gavard JA, Lustman PJ, Clouse RE. Prevalence of depression in adults with diabetes: an epidemiological evaluation. Diabetes Care 1993 Aug; 16(8): 1167–78PubMedCrossRef Gavard JA, Lustman PJ, Clouse RE. Prevalence of depression in adults with diabetes: an epidemiological evaluation. Diabetes Care 1993 Aug; 16(8): 1167–78PubMedCrossRef
7.
Zurück zum Zitat Lustman PJ, Anderson RJ, Freedland KE, et al. Depression and poor glycemic control: a meta-analytic review of the literature. Diabetes Care 2000 Jul; 23(7): 934–42PubMedCrossRef Lustman PJ, Anderson RJ, Freedland KE, et al. Depression and poor glycemic control: a meta-analytic review of the literature. Diabetes Care 2000 Jul; 23(7): 934–42PubMedCrossRef
8.
Zurück zum Zitat Casey DE. Metabolic issues and cardiovascular disease in patients with psychiatric disorders. Am J Med 2005 Apr; 118 Suppl. 2: 15S–22SPubMed Casey DE. Metabolic issues and cardiovascular disease in patients with psychiatric disorders. Am J Med 2005 Apr; 118 Suppl. 2: 15S–22SPubMed
9.
Zurück zum Zitat Heiskanen TH, Niskanen LK, Hintikka JJ, et al. Metabolic syndrome and depression: a cross-sectional analysis. J Clin Psychiatry 2006 Sep; 67(9): 1422–7PubMedCrossRef Heiskanen TH, Niskanen LK, Hintikka JJ, et al. Metabolic syndrome and depression: a cross-sectional analysis. J Clin Psychiatry 2006 Sep; 67(9): 1422–7PubMedCrossRef
10.
Zurück zum Zitat McCaffery JM, Niaura R, Todaro JF, et al. Depressive symptoms and metabolic risk in adult male twins enrolled in the National Heart, Lung, and Blood Institute twin study. Psychosom Med 2003 May; 65(3): 490–7PubMedCrossRef McCaffery JM, Niaura R, Todaro JF, et al. Depressive symptoms and metabolic risk in adult male twins enrolled in the National Heart, Lung, and Blood Institute twin study. Psychosom Med 2003 May; 65(3): 490–7PubMedCrossRef
11.
Zurück zum Zitat McIntyre RS, Soczynska JK, Konarski JZ, et al. Should depressive syndromes be reclassified as “metabolic syndrome type II”? Ann Clin Psychiatry 2007 Oct; 19(4): 257–64PubMedCrossRef McIntyre RS, Soczynska JK, Konarski JZ, et al. Should depressive syndromes be reclassified as “metabolic syndrome type II”? Ann Clin Psychiatry 2007 Oct; 19(4): 257–64PubMedCrossRef
12.
Zurück zum Zitat Toalson P, Ahmed S, Hardy T, et al. The metabolic syndrome in patients with severe mental illnesses. Prim Care Companion J Clin Psychiatry 2004; 6(4): 152–8PubMedCrossRef Toalson P, Ahmed S, Hardy T, et al. The metabolic syndrome in patients with severe mental illnesses. Prim Care Companion J Clin Psychiatry 2004; 6(4): 152–8PubMedCrossRef
13.
Zurück zum Zitat Toker S, Shirom A, Melamed S. Depression and the metabolic syndrome: gender-dependent associations. Depress Anxiety 2008; 25(8): 661–9PubMedCrossRef Toker S, Shirom A, Melamed S. Depression and the metabolic syndrome: gender-dependent associations. Depress Anxiety 2008; 25(8): 661–9PubMedCrossRef
14.
Zurück zum Zitat Weber-Hamann B, Werner M, Hentschel F, et al. Metabolic changes in elderly patients with major depression: evidence for increased accumulation of visceral fat at follow-up. Psychoneuroendocrinology 2006 Apr; 31(3): 347–54PubMedCrossRef Weber-Hamann B, Werner M, Hentschel F, et al. Metabolic changes in elderly patients with major depression: evidence for increased accumulation of visceral fat at follow-up. Psychoneuroendocrinology 2006 Apr; 31(3): 347–54PubMedCrossRef
15.
Zurück zum Zitat Koponen H, Jokelainen J, Keinanen-Kiukaanniemi S, et al. Metabolic syndrome predisposes to depressive symptoms: a population-based 7-Year follow-up study. J Clin Psychiatry 2008 Feb; 69(2): 178–82PubMedCrossRef Koponen H, Jokelainen J, Keinanen-Kiukaanniemi S, et al. Metabolic syndrome predisposes to depressive symptoms: a population-based 7-Year follow-up study. J Clin Psychiatry 2008 Feb; 69(2): 178–82PubMedCrossRef
16.
Zurück zum Zitat Teixeira PJ, Rocha FL. The prevalence of metabolic syndrome among psychiatric inpatients in Brazil. Rev Bras Psiquiatr 2007 Dec; 29(4): 330–6PubMedCrossRef Teixeira PJ, Rocha FL. The prevalence of metabolic syndrome among psychiatric inpatients in Brazil. Rev Bras Psiquiatr 2007 Dec; 29(4): 330–6PubMedCrossRef
17.
Zurück zum Zitat Fontbonne A, Charles MA, Juhan-Vague I, et al. The effect of metformin on the metabolic abnormalities associated with upper-body fat distribution: BIGPRO Study Group. Diabetes Care 1996 Sep; 19(9): 920–6PubMedCrossRef Fontbonne A, Charles MA, Juhan-Vague I, et al. The effect of metformin on the metabolic abnormalities associated with upper-body fat distribution: BIGPRO Study Group. Diabetes Care 1996 Sep; 19(9): 920–6PubMedCrossRef
18.
Zurück zum Zitat Raikkonen K, Matthews KA, Kuller LH. The relationship between psychological risk attributes and the metabolic syndrome in healthy women: antecedent or consequence? Metabolism 2002 Dec; 51(12): 1573–7PubMedCrossRef Raikkonen K, Matthews KA, Kuller LH. The relationship between psychological risk attributes and the metabolic syndrome in healthy women: antecedent or consequence? Metabolism 2002 Dec; 51(12): 1573–7PubMedCrossRef
19.
Zurück zum Zitat McIntyre RS. Psychotropic drugs and adverse events in the treatment of bipolar disorders revisited. J Clin Psychiatry 2002; 63 Suppl. 3: 15–20 McIntyre RS. Psychotropic drugs and adverse events in the treatment of bipolar disorders revisited. J Clin Psychiatry 2002; 63 Suppl. 3: 15–20
20.
Zurück zum Zitat McIntyre RS, Konarski JZ, Keck PE. Psychotropic-induced weight gain: liability, mechanisms and treatment approaches. In: McElroy SL, Allison DB, Bray GA, editors. Obesity and mental disorders. New York: Taylor & Francis, 2005: 307–52 McIntyre RS, Konarski JZ, Keck PE. Psychotropic-induced weight gain: liability, mechanisms and treatment approaches. In: McElroy SL, Allison DB, Bray GA, editors. Obesity and mental disorders. New York: Taylor & Francis, 2005: 307–52
21.
Zurück zum Zitat McIntyre RS, Soczynska JK, Konarski JZ, et al. The effect of antidepressants on lipid homeostasis: a cardiac safety concern?Expert Opin Drug Saf 2006 Jul; 5(4): 523–37PubMedCrossRef McIntyre RS, Soczynska JK, Konarski JZ, et al. The effect of antidepressants on lipid homeostasis: a cardiac safety concern?Expert Opin Drug Saf 2006 Jul; 5(4): 523–37PubMedCrossRef
22.
Zurück zum Zitat McIntyre RS, Soczynska JK, Konarski JZ, et al. The effect of antidepressants on glucose homeostasis and insulin sensitivity: synthesis and mechanisms. Expert Opin Drug Saf 2006 Jan; 5(1): 157–68PubMedCrossRef McIntyre RS, Soczynska JK, Konarski JZ, et al. The effect of antidepressants on glucose homeostasis and insulin sensitivity: synthesis and mechanisms. Expert Opin Drug Saf 2006 Jan; 5(1): 157–68PubMedCrossRef
23.
Zurück zum Zitat van Praag HM, Leijnse B. Depression, glucose tolerance, peripheral glucose uptake and their alterations under the influence of anti-depressive drugs of the hydrazine type. Psychopharmacologia 1965 Jun 1; 8(1): 67–78PubMedCrossRef van Praag HM, Leijnse B. Depression, glucose tolerance, peripheral glucose uptake and their alterations under the influence of anti-depressive drugs of the hydrazine type. Psychopharmacologia 1965 Jun 1; 8(1): 67–78PubMedCrossRef
24.
Zurück zum Zitat van Pragg H, Leijnse B. The influence of some antidepressives of the hydrazine type on the glucose metabolism in depressed patients. Clin Chim Acta 1963 May; 8: 466–75CrossRef van Pragg H, Leijnse B. The influence of some antidepressives of the hydrazine type on the glucose metabolism in depressed patients. Clin Chim Acta 1963 May; 8: 466–75CrossRef
25.
Zurück zum Zitat Van Praag HM, Leijnse B. The xylose metabolism in depressed patients and its alterations under the influence of antidepressive hydrazines. Clinica Chimica Acta 1965; 11: 13–23CrossRef Van Praag HM, Leijnse B. The xylose metabolism in depressed patients and its alterations under the influence of antidepressive hydrazines. Clinica Chimica Acta 1965; 11: 13–23CrossRef
26.
Zurück zum Zitat Cantu TG, Korek JS. Monoamine oxidase inhibitors and weight gain. Drug Intell Clin Pharm 1988 Oct; 22(10): 755–9PubMed Cantu TG, Korek JS. Monoamine oxidase inhibitors and weight gain. Drug Intell Clin Pharm 1988 Oct; 22(10): 755–9PubMed
27.
Zurück zum Zitat Davidson J, Turnbull CD. The effects of isocarboxazid on blood pressure and pulse. J Clin Psychopharmacol 1986 Jun; 6(3): 139–43PubMedCrossRef Davidson J, Turnbull CD. The effects of isocarboxazid on blood pressure and pulse. J Clin Psychopharmacol 1986 Jun; 6(3): 139–43PubMedCrossRef
28.
Zurück zum Zitat Rabkin J, Quitkin F, Harrison W, et al. Adverse reactions to monoamine oxidase inhibitors: part I. A comparative study. J Clin Psychopharmacol 1984 Oct; 4(5): 270–8 Rabkin J, Quitkin F, Harrison W, et al. Adverse reactions to monoamine oxidase inhibitors: part I. A comparative study. J Clin Psychopharmacol 1984 Oct; 4(5): 270–8
29.
Zurück zum Zitat Kennedy SH, Lam RW, Parikh SV, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults: introduction. J Affect Disord 2009 Oct; 117 Suppl. 1: S1–2PubMedCrossRef Kennedy SH, Lam RW, Parikh SV, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults: introduction. J Affect Disord 2009 Oct; 117 Suppl. 1: S1–2PubMedCrossRef
30.
Zurück zum Zitat Nair NP, Amin M, Holm P, et al. Moclobemide and nortriptyline in elderly depressed patients: a randomized, multicentre trial against placebo. J Affect Disord 1995 Jan 11; 33(1): 1–9PubMedCrossRef Nair NP, Amin M, Holm P, et al. Moclobemide and nortriptyline in elderly depressed patients: a randomized, multicentre trial against placebo. J Affect Disord 1995 Jan 11; 33(1): 1–9PubMedCrossRef
31.
Zurück zum Zitat Vanderkooy JD, Kennedy SH, Bagby RM. Antidepressant side effects in depression patients treated in a naturalistic setting: a study of bupropion, moclobemide, paroxetine, sertraline, and venlafaxine. Can J Psychiatry 2002 Mar; 47(2): 174–80PubMed Vanderkooy JD, Kennedy SH, Bagby RM. Antidepressant side effects in depression patients treated in a naturalistic setting: a study of bupropion, moclobemide, paroxetine, sertraline, and venlafaxine. Can J Psychiatry 2002 Mar; 47(2): 174–80PubMed
32.
Zurück zum Zitat Vaz-Serra A, Figueira ML, Firmino H, et al. Multicenter double-blind study of moclobemide and maprotiline. Clin Neuropharmacol 1994; 17 Suppl. 1: S38–49PubMedCrossRef Vaz-Serra A, Figueira ML, Firmino H, et al. Multicenter double-blind study of moclobemide and maprotiline. Clin Neuropharmacol 1994; 17 Suppl. 1: S38–49PubMedCrossRef
33.
Zurück zum Zitat Bakish D, Bradwejn J, Nair N, et al. A comparison of moclobemide, amitriptyline and placebo in depression: a Canadian multicentre study. Psychopharmacology (Berl) 1992; 106 Suppl. : S98–101CrossRef Bakish D, Bradwejn J, Nair N, et al. A comparison of moclobemide, amitriptyline and placebo in depression: a Canadian multicentre study. Psychopharmacology (Berl) 1992; 106 Suppl. : S98–101CrossRef
34.
Zurück zum Zitat Moll E, Neumann N, Schmid-Burgk W, et al. Safety and efficacy during long-term treatment with moclobemide. Clin Neuropharmacol 1994; 17 Suppl. 1: S74–87PubMedCrossRef Moll E, Neumann N, Schmid-Burgk W, et al. Safety and efficacy during long-term treatment with moclobemide. Clin Neuropharmacol 1994; 17 Suppl. 1: S74–87PubMedCrossRef
35.
Zurück zum Zitat Ghaeli P, Shahsavand E, Mesbahi M, et al. Comparing the effects of 8-week treatment with fluoxetine and imipramine on fasting blood glucose of patients with major depressive disorder. J Clin Psychopharmacol 2004 Aug; 24(4): 386–8PubMedCrossRef Ghaeli P, Shahsavand E, Mesbahi M, et al. Comparing the effects of 8-week treatment with fluoxetine and imipramine on fasting blood glucose of patients with major depressive disorder. J Clin Psychopharmacol 2004 Aug; 24(4): 386–8PubMedCrossRef
36.
Zurück zum Zitat Lustman PJ, Griffith LS, Clouse RE, et al. Effects of nortriptyline on depression and glycemic control in diabetes: results of a double-blind, placebo-controlled trial. Psychosom Med 1997 May; 59(3): 241–50PubMed Lustman PJ, Griffith LS, Clouse RE, et al. Effects of nortriptyline on depression and glycemic control in diabetes: results of a double-blind, placebo-controlled trial. Psychosom Med 1997 May; 59(3): 241–50PubMed
37.
Zurück zum Zitat Moosa MY, Panz VR, Jeenah FY, et al. African women with depression: the effect of imipramine and fluoxetine on body mass index and leptin secretion. J Clin Psychopharmacol 2003 Dec; 23(6): 549–52PubMedCrossRef Moosa MY, Panz VR, Jeenah FY, et al. African women with depression: the effect of imipramine and fluoxetine on body mass index and leptin secretion. J Clin Psychopharmacol 2003 Dec; 23(6): 549–52PubMedCrossRef
38.
Zurück zum Zitat Yeragani VK, Pohl R, Balon R, et al. Increased serum total cholesterol to HDL-cholesterol ratio after imipramine. Psychiatry Res 1990 May; 32(2): 207–9PubMedCrossRef Yeragani VK, Pohl R, Balon R, et al. Increased serum total cholesterol to HDL-cholesterol ratio after imipramine. Psychiatry Res 1990 May; 32(2): 207–9PubMedCrossRef
39.
Zurück zum Zitat Hinze-Selch D, Schuld A, Kraus T, et al. Effects of antidepressants on weight and on the plasma levels of leptin, TNF-alpha and soluble TNF receptors: a longitudinal study in patients treated with amitriptyline or paroxetine. Neuropsychopharmacology 2000 Jul; 23(1): 13–9PubMedCrossRef Hinze-Selch D, Schuld A, Kraus T, et al. Effects of antidepressants on weight and on the plasma levels of leptin, TNF-alpha and soluble TNF receptors: a longitudinal study in patients treated with amitriptyline or paroxetine. Neuropsychopharmacology 2000 Jul; 23(1): 13–9PubMedCrossRef
40.
Zurück zum Zitat Berilgen MS, Bulut S, Gonen M, et al. Comparison of the effects of amitriptyline and flunarizine on weight gain and serum leptin, C peptide and insulin levels when used as migraine preventive treatment. Cephalalgia 2005 Nov; 25(11): 1048–53PubMedCrossRef Berilgen MS, Bulut S, Gonen M, et al. Comparison of the effects of amitriptyline and flunarizine on weight gain and serum leptin, C peptide and insulin levels when used as migraine preventive treatment. Cephalalgia 2005 Nov; 25(11): 1048–53PubMedCrossRef
41.
Zurück zum Zitat Paykel ES, Mueller PS, De la Vergne PM. Amitriptyline, weight gain and carbohydrate craving: a side effect. Br J Psychiatry 1973 Nov; 123(576): 501–7PubMedCrossRef Paykel ES, Mueller PS, De la Vergne PM. Amitriptyline, weight gain and carbohydrate craving: a side effect. Br J Psychiatry 1973 Nov; 123(576): 501–7PubMedCrossRef
42.
Zurück zum Zitat Sansone RA, Wiederman MW, Shrader JA. Naturalistic study of the weight effects of amitriptyline, fluoxetine, and sertraline in an outpatient medical setting. J Clin Psychopharmacol 2000 Apr; 20(2): 272–4PubMedCrossRef Sansone RA, Wiederman MW, Shrader JA. Naturalistic study of the weight effects of amitriptyline, fluoxetine, and sertraline in an outpatient medical setting. J Clin Psychopharmacol 2000 Apr; 20(2): 272–4PubMedCrossRef
43.
Zurück zum Zitat Kopf D, Westphal S, Luley CW, et al. Lipid metabolism and insulin resistance in depressed patients: significance of weight, hypercortisolism, and antidepressant treatment. J Clin Psychopharmacol 2004 Oct; 24(5): 527–31PubMedCrossRef Kopf D, Westphal S, Luley CW, et al. Lipid metabolism and insulin resistance in depressed patients: significance of weight, hypercortisolism, and antidepressant treatment. J Clin Psychopharmacol 2004 Oct; 24(5): 527–31PubMedCrossRef
44.
Zurück zum Zitat Fernstrom MH, Kupfer DJ. Antidepressant-induced weight gain: a comparison study of four medications. Psychiatry Res 1988 Dec; 26(3): 265–71PubMedCrossRef Fernstrom MH, Kupfer DJ. Antidepressant-induced weight gain: a comparison study of four medications. Psychiatry Res 1988 Dec; 26(3): 265–71PubMedCrossRef
45.
Zurück zum Zitat Berken GH, Weinstein DO, Stern WC. Weight gain: a side-effect of tricyclic antidepressants. J Affect Disord 1984 Oct; 7(2): 133–8PubMedCrossRef Berken GH, Weinstein DO, Stern WC. Weight gain: a side-effect of tricyclic antidepressants. J Affect Disord 1984 Oct; 7(2): 133–8PubMedCrossRef
46.
Zurück zum Zitat Frank E, Kupfer DJ, Buhari A, et al. Imipramine and weight gain during the long-term treatment of recurrent depression. J Affect Disord 1992 Sep; 26(1): 65–72PubMedCrossRef Frank E, Kupfer DJ, Buhari A, et al. Imipramine and weight gain during the long-term treatment of recurrent depression. J Affect Disord 1992 Sep; 26(1): 65–72PubMedCrossRef
47.
Zurück zum Zitat Kupfer DJ, Coble PA, Rubinstein D. Changes in weight during treatment for depression. Psychosom Med 1979 Nov; 41(7): 535–44PubMed Kupfer DJ, Coble PA, Rubinstein D. Changes in weight during treatment for depression. Psychosom Med 1979 Nov; 41(7): 535–44PubMed
48.
Zurück zum Zitat Levitt AJ, Joffe RT, Esche I, et al. The effect of desipramine on body weight in depression. J Clin Psychiatry 1987 Jan; 48(1): 27–8PubMed Levitt AJ, Joffe RT, Esche I, et al. The effect of desipramine on body weight in depression. J Clin Psychiatry 1987 Jan; 48(1): 27–8PubMed
49.
Zurück zum Zitat Sussman N, Ginsberg DL, Bikoff J. Effects of nefazodone on body weight: a pooled analysis of selective serotonin reuptake inhibitor- and imipramine-controlled trials. J Clin Psychiatry 2001 Apr; 62(4): 256–60PubMedCrossRef Sussman N, Ginsberg DL, Bikoff J. Effects of nefazodone on body weight: a pooled analysis of selective serotonin reuptake inhibitor- and imipramine-controlled trials. J Clin Psychiatry 2001 Apr; 62(4): 256–60PubMedCrossRef
50.
Zurück zum Zitat Weisler RH, Johnston JA, Lineberry CG, et al. Comparison of bupropion and trazodone for the treatment of major depression. J Clin Psychopharmacol 1994 Jun;14(3): 170–9PubMedCrossRef Weisler RH, Johnston JA, Lineberry CG, et al. Comparison of bupropion and trazodone for the treatment of major depression. J Clin Psychopharmacol 1994 Jun;14(3): 170–9PubMedCrossRef
51.
Zurück zum Zitat Perry PJ, Garvey MJ, Dunner DL, et al. A report of trazodone-associated laboratory abnormalities. Ther Drug Monit 1990 Nov; 12(6): 517–9PubMedCrossRef Perry PJ, Garvey MJ, Dunner DL, et al. A report of trazodone-associated laboratory abnormalities. Ther Drug Monit 1990 Nov; 12(6): 517–9PubMedCrossRef
52.
Zurück zum Zitat Maheux P, Ducros F, Bourque J, et al. Fluoxetine improves insulin sensitivity in obese patients with non-insulin-dependent diabetes mellitus independently of weight loss. Int J Obes Relat Metab Disord 1997 Feb; 21(2): 97–102PubMedCrossRef Maheux P, Ducros F, Bourque J, et al. Fluoxetine improves insulin sensitivity in obese patients with non-insulin-dependent diabetes mellitus independently of weight loss. Int J Obes Relat Metab Disord 1997 Feb; 21(2): 97–102PubMedCrossRef
53.
Zurück zum Zitat O’Kane M, Wiles PG, Wales JK. Fluoxetine in the treatment of obese type 2 diabetic patients. Diabet Med 1994 Jan; 11(1): 105–10PubMedCrossRef O’Kane M, Wiles PG, Wales JK. Fluoxetine in the treatment of obese type 2 diabetic patients. Diabet Med 1994 Jan; 11(1): 105–10PubMedCrossRef
54.
Zurück zum Zitat Potter van Loon BJ, Radder JK, Frolich M, et al. Fluoxetine increases insulin action in obese type II (non-insulin dependent) diabetic patients. Int J Obes Relat Metab Disord 1992 Dec; 16 Suppl. 4: S55–61 Potter van Loon BJ, Radder JK, Frolich M, et al. Fluoxetine increases insulin action in obese type II (non-insulin dependent) diabetic patients. Int J Obes Relat Metab Disord 1992 Dec; 16 Suppl. 4: S55–61
55.
Zurück zum Zitat Gray DS, Fujioka K, Devine W, et al. A randomized double-blind clinical trial of fluoxetine in obese diabetics. Int J Obes Relat Metab Disord 1992 Dec; 16 Suppl. 4: S67–72PubMed Gray DS, Fujioka K, Devine W, et al. A randomized double-blind clinical trial of fluoxetine in obese diabetics. Int J Obes Relat Metab Disord 1992 Dec; 16 Suppl. 4: S67–72PubMed
56.
Zurück zum Zitat Weber-Hamann B, Gilles M, Lederbogen F, et al. Improved insulin sensitivity in 80 nondiabetic patients with MDD after clinical remission in a double-blind, randomized trial of amitriptyline and paroxetine. J Clin Psychiatry 2006 Dec; 67(12): 1856–61PubMedCrossRef Weber-Hamann B, Gilles M, Lederbogen F, et al. Improved insulin sensitivity in 80 nondiabetic patients with MDD after clinical remission in a double-blind, randomized trial of amitriptyline and paroxetine. J Clin Psychiatry 2006 Dec; 67(12): 1856–61PubMedCrossRef
57.
Zurück zum Zitat Chen YC, Shen YC, Hung YJ, et al. Comparisons of glucose-insulin homeostasis following maprotiline and fluoxetine treatment in depressed males. J Affect Disord 2007 Nov; 103(1–3): 257–61PubMedCrossRef Chen YC, Shen YC, Hung YJ, et al. Comparisons of glucose-insulin homeostasis following maprotiline and fluoxetine treatment in depressed males. J Affect Disord 2007 Nov; 103(1–3): 257–61PubMedCrossRef
58.
Zurück zum Zitat Lara N, Baker GB, Archer SL, et al. Increased cholesterol levels during paroxetine administration in healthy men. J Clin Psychiatry 2003 Dec; 64(12): 1455–9PubMedCrossRef Lara N, Baker GB, Archer SL, et al. Increased cholesterol levels during paroxetine administration in healthy men. J Clin Psychiatry 2003 Dec; 64(12): 1455–9PubMedCrossRef
59.
Zurück zum Zitat Hewer W, Rost W, Gattaz WF. Cardiovascular effects of fluvoxamine and maprotiline in depressed patients. Eur Arch Psychiatry Clin Neurosci 1995; 246(1): 1–6PubMedCrossRef Hewer W, Rost W, Gattaz WF. Cardiovascular effects of fluvoxamine and maprotiline in depressed patients. Eur Arch Psychiatry Clin Neurosci 1995; 246(1): 1–6PubMedCrossRef
60.
Zurück zum Zitat Kauffman RP, Castracane VD, White DL, et al. Impact of the selective serotonin reuptake inhibitor citalopram on insulin sensitivity, leptin and basal cortisol secretion in depressed and non-depressed euglycemic women of reproductive age. Gynecol Endocrinol 2005 Sep; 21(3): 129–37PubMedCrossRef Kauffman RP, Castracane VD, White DL, et al. Impact of the selective serotonin reuptake inhibitor citalopram on insulin sensitivity, leptin and basal cortisol secretion in depressed and non-depressed euglycemic women of reproductive age. Gynecol Endocrinol 2005 Sep; 21(3): 129–37PubMedCrossRef
61.
Zurück zum Zitat Aberg-Wistedt A, Agren H, Ekselius L, et al. Sertraline versus paroxetine in major depression: clinical outcome after six months of continuous therapy. J Clin Psychopharmacol 2000 Dec; 20(6): 645–52PubMedCrossRef Aberg-Wistedt A, Agren H, Ekselius L, et al. Sertraline versus paroxetine in major depression: clinical outcome after six months of continuous therapy. J Clin Psychopharmacol 2000 Dec; 20(6): 645–52PubMedCrossRef
62.
Zurück zum Zitat Fava M, Judge R, Hoog SL, et al. Fluoxetine versus sertraline and paroxetine in major depressive disorder: changes in weight with long-term treatment. J Clin Psychiatry 2000 Nov; 61(11): 863–7PubMedCrossRef Fava M, Judge R, Hoog SL, et al. Fluoxetine versus sertraline and paroxetine in major depressive disorder: changes in weight with long-term treatment. J Clin Psychiatry 2000 Nov; 61(11): 863–7PubMedCrossRef
63.
Zurück zum Zitat Montgomery SA, Reimitz PE, Zivkov M. Mirtazapine versus amitriptyline in the long-term treatment of depression: a double-blind placebo-controlled study. Int Clin Psychopharmacol 1998 Mar; 13(2): 63–73PubMedCrossRef Montgomery SA, Reimitz PE, Zivkov M. Mirtazapine versus amitriptyline in the long-term treatment of depression: a double-blind placebo-controlled study. Int Clin Psychopharmacol 1998 Mar; 13(2): 63–73PubMedCrossRef
64.
Zurück zum Zitat Daubresse JC, Kolanowski J, Krzentowski G, et al. Usefulness of fluoxetine in obese non-insulin-dependent diabetics: a multicenter study. Obes Res 1996 Jul; 4(4): 391–6PubMedCrossRef Daubresse JC, Kolanowski J, Krzentowski G, et al. Usefulness of fluoxetine in obese non-insulin-dependent diabetics: a multicenter study. Obes Res 1996 Jul; 4(4): 391–6PubMedCrossRef
65.
Zurück zum Zitat Michelson D, Amsterdam JD, Quitkin FM, et al. Changes in weight during a 1-year trial of fluoxetine. Am J Psychiatry 1999 Aug; 156(8): 1170–6PubMed Michelson D, Amsterdam JD, Quitkin FM, et al. Changes in weight during a 1-year trial of fluoxetine. Am J Psychiatry 1999 Aug; 156(8): 1170–6PubMed
66.
Zurück zum Zitat Bilici M, Efe H, Koroglu MA, et al. Antioxidative enzyme activities and lipid peroxidation in major depression: alterations by antidepressant treatments. J Affect Disord 2001 Apr; 64(1): 43–51PubMedCrossRef Bilici M, Efe H, Koroglu MA, et al. Antioxidative enzyme activities and lipid peroxidation in major depression: alterations by antidepressant treatments. J Affect Disord 2001 Apr; 64(1): 43–51PubMedCrossRef
67.
Zurück zum Zitat Seo HJ, Jung YE, Woo YS, et al. Effect of augmented atypical antipsychotics on weight change in patients with major depressive disorder in a naturalistic setting. Hum Psychopharmacol 2009 Mar; 24(2): 135–43PubMedCrossRef Seo HJ, Jung YE, Woo YS, et al. Effect of augmented atypical antipsychotics on weight change in patients with major depressive disorder in a naturalistic setting. Hum Psychopharmacol 2009 Mar; 24(2): 135–43PubMedCrossRef
68.
Zurück zum Zitat Bielski RJ, Ventura D, Chang CC. A double-blind comparison of escitalopram and venlafaxine extended release in the treatment of major depressive disorder. J Clin Psychiatry 2004 Sep; 65(9): 1190–6PubMedCrossRef Bielski RJ, Ventura D, Chang CC. A double-blind comparison of escitalopram and venlafaxine extended release in the treatment of major depressive disorder. J Clin Psychiatry 2004 Sep; 65(9): 1190–6PubMedCrossRef
69.
Zurück zum Zitat Bielski RJ, Bose A, Chang CC. A double-blind comparison of escitalopram and paroxetine in the long-term treatment of generalized anxiety disorder. Ann Clin Psychiatry 2005 Apr; 17(2): 65–9PubMedCrossRef Bielski RJ, Bose A, Chang CC. A double-blind comparison of escitalopram and paroxetine in the long-term treatment of generalized anxiety disorder. Ann Clin Psychiatry 2005 Apr; 17(2): 65–9PubMedCrossRef
70.
Zurück zum Zitat Gulseren L, Gulseren S, Hekimsoy Z, et al. Comparison of fluoxetine and paroxetine in type II diabetes mellitus patients. Arch Med Res 2005 Mar; 36(2): 159–65PubMedCrossRef Gulseren L, Gulseren S, Hekimsoy Z, et al. Comparison of fluoxetine and paroxetine in type II diabetes mellitus patients. Arch Med Res 2005 Mar; 36(2): 159–65PubMedCrossRef
71.
Zurück zum Zitat Ljung T, Ahlberg AC, Holm G, et al. Treatment of abdominally obese men with a serotonin reuptake inhibitor: a pilot study. J Intern Med 2001 Sep; 250(3): 219–24PubMedCrossRef Ljung T, Ahlberg AC, Holm G, et al. Treatment of abdominally obese men with a serotonin reuptake inhibitor: a pilot study. J Intern Med 2001 Sep; 250(3): 219–24PubMedCrossRef
72.
Zurück zum Zitat Lu ML, Lane HY, Lin SK, et al. Adjunctive fluvoxamine inhibits clozapine-related weight gain and metabolic disturbances. J Clin Psychiatry 2004 Jun; 65(6): 766–71PubMedCrossRef Lu ML, Lane HY, Lin SK, et al. Adjunctive fluvoxamine inhibits clozapine-related weight gain and metabolic disturbances. J Clin Psychiatry 2004 Jun; 65(6): 766–71PubMedCrossRef
73.
Zurück zum Zitat Moore N, Verdoux H, Fantino B. Prospective, multicentre, randomized, double-blind study of the efficacy of escitalopram versus citalopram in outpatient treatment of major depressive disorder. Int Clin Psychopharmacol 2005 May; 20(3): 131–7PubMedCrossRef Moore N, Verdoux H, Fantino B. Prospective, multicentre, randomized, double-blind study of the efficacy of escitalopram versus citalopram in outpatient treatment of major depressive disorder. Int Clin Psychopharmacol 2005 May; 20(3): 131–7PubMedCrossRef
74.
Zurück zum Zitat Paile-Hyvarinen M, Wahlbeck K, Eriksson JG. Quality of life and metabolic status in mildly depressed women with type 2 diabetes treated with paroxetine: a single-blind randomised placebo controlled trial. BMC Fam Pract 2003 May 14; 4: 7PubMedCrossRef Paile-Hyvarinen M, Wahlbeck K, Eriksson JG. Quality of life and metabolic status in mildly depressed women with type 2 diabetes treated with paroxetine: a single-blind randomised placebo controlled trial. BMC Fam Pract 2003 May 14; 4: 7PubMedCrossRef
75.
Zurück zum Zitat Sonawalla SB, Papakostas GI, Petersen TJ, et al. Elevated cholesterol levels associated with nonresponse to fluoxetine treatment in major depressive disorder. Psychosomatics 2002 Jul; 43(4): 310–6PubMedCrossRef Sonawalla SB, Papakostas GI, Petersen TJ, et al. Elevated cholesterol levels associated with nonresponse to fluoxetine treatment in major depressive disorder. Psychosomatics 2002 Jul; 43(4): 310–6PubMedCrossRef
76.
Zurück zum Zitat Weber-Hamann B, Kratzsch J, Kopf D, et al. Resistin and adiponectin in major depression: the association with free cortisol and effects of antidepressant treatment. J Psychiatr Res 2007 Apr; 41(3–4): 344–50PubMedCrossRef Weber-Hamann B, Kratzsch J, Kopf D, et al. Resistin and adiponectin in major depression: the association with free cortisol and effects of antidepressant treatment. J Psychiatr Res 2007 Apr; 41(3–4): 344–50PubMedCrossRef
77.
Zurück zum Zitat Hardy T, Sachson R, Shen S, et al. Does treatment with duloxetine for neuropathic pain impact glycemic control? Diabetes Care 2007 Jan; 30(1): 21–6PubMedCrossRef Hardy T, Sachson R, Shen S, et al. Does treatment with duloxetine for neuropathic pain impact glycemic control? Diabetes Care 2007 Jan; 30(1): 21–6PubMedCrossRef
78.
Zurück zum Zitat Wernicke JF, Wang F, Pritchett YL, et al. An open-label 52-week clinical extension comparing duloxetine with routine care in patients with diabetic peripheral neuropathic pain. Pain Med 2007 Sep; 8(6): 503–13PubMedCrossRef Wernicke JF, Wang F, Pritchett YL, et al. An open-label 52-week clinical extension comparing duloxetine with routine care in patients with diabetic peripheral neuropathic pain. Pain Med 2007 Sep; 8(6): 503–13PubMedCrossRef
79.
Zurück zum Zitat Boyer P, Montgomery S, Lepola U, et al. Efficacy, safety, and tolerability of fixed-dose desvenlafaxine 50 and 100 mg/day for major depressive disorder in a placebo-controlled trial. Int Clin Psychopharmacol 2008 Sep; 23(5): 243–53PubMedCrossRef Boyer P, Montgomery S, Lepola U, et al. Efficacy, safety, and tolerability of fixed-dose desvenlafaxine 50 and 100 mg/day for major depressive disorder in a placebo-controlled trial. Int Clin Psychopharmacol 2008 Sep; 23(5): 243–53PubMedCrossRef
80.
Zurück zum Zitat Detke MJ, Lu Y, Goldstein DJ, et al. Duloxetine, 60 mg once daily, for major depressive disorder: a randomized double-blind placebo-controlled trial. J Clin Psychiatry 2002 Apr; 63(4): 308–15PubMedCrossRef Detke MJ, Lu Y, Goldstein DJ, et al. Duloxetine, 60 mg once daily, for major depressive disorder: a randomized double-blind placebo-controlled trial. J Clin Psychiatry 2002 Apr; 63(4): 308–15PubMedCrossRef
81.
Zurück zum Zitat Liebowitz MR, Yeung PP, Entsuah R. A randomized, double-blind, placebo-controlled trial of desvenlafaxine succinate in adult outpatients with major depressive disorder. J Clin Psychiatry 2007 Nov; 68(11): 1663–72PubMedCrossRef Liebowitz MR, Yeung PP, Entsuah R. A randomized, double-blind, placebo-controlled trial of desvenlafaxine succinate in adult outpatients with major depressive disorder. J Clin Psychiatry 2007 Nov; 68(11): 1663–72PubMedCrossRef
82.
Zurück zum Zitat Keller MB, Trivedi MH, Thase ME, et al. The Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) study: outcomes from the 2-year and combined maintenance phases. J Clin Psychiatry 2007 Aug; 68(8): 1246–56PubMedCrossRef Keller MB, Trivedi MH, Thase ME, et al. The Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) study: outcomes from the 2-year and combined maintenance phases. J Clin Psychiatry 2007 Aug; 68(8): 1246–56PubMedCrossRef
83.
Zurück zum Zitat Keller MB, Trivedi MH, Thase ME, et al. The Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) study: outcomes from the acute and continuation phases. Biol Psychiatry 2007 Dec 15; 62(12): 1371–9PubMedCrossRef Keller MB, Trivedi MH, Thase ME, et al. The Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) study: outcomes from the acute and continuation phases. Biol Psychiatry 2007 Dec 15; 62(12): 1371–9PubMedCrossRef
84.
Zurück zum Zitat Tourian KA, Leurent C, Graepel J, et al. Desvenlafaxine and weight change in major depressive disorder. Prim Care Companion J Clin Psychiatry 2010; 12 (1): PCC.08m00746 Tourian KA, Leurent C, Graepel J, et al. Desvenlafaxine and weight change in major depressive disorder. Prim Care Companion J Clin Psychiatry 2010; 12 (1): PCC.08m00746
85.
Zurück zum Zitat Detke MJ, Wiltse CG, Mallinckrodt CH, et al. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial. Eur Neuropsychopharmacol 2004 Dec; 14(6): 457–70PubMedCrossRef Detke MJ, Wiltse CG, Mallinckrodt CH, et al. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial. Eur Neuropsychopharmacol 2004 Dec; 14(6): 457–70PubMedCrossRef
86.
Zurück zum Zitat Liebowitz MR, Mangano RM, Bradwejn J, et al. A randomized controlled trial of venlafaxine extended release in generalized social anxiety disorder. J Clin Psychiatry 2005 Feb; 66(2): 238–47PubMedCrossRef Liebowitz MR, Mangano RM, Bradwejn J, et al. A randomized controlled trial of venlafaxine extended release in generalized social anxiety disorder. J Clin Psychiatry 2005 Feb; 66(2): 238–47PubMedCrossRef
87.
Zurück zum Zitat Raskin J, Wang F, Pritchett YL, et al. Duloxetine for patients with diabetic peripheral neuropathic pain: a 6-month open-label safety study. Pain Med 2006 Sep; 7(5): 373–85PubMedCrossRef Raskin J, Wang F, Pritchett YL, et al. Duloxetine for patients with diabetic peripheral neuropathic pain: a 6-month open-label safety study. Pain Med 2006 Sep; 7(5): 373–85PubMedCrossRef
88.
Zurück zum Zitat Wohlreich MM, Mallinckrodt CH, Prakash A, et al. Duloxetine for the treatment of major depressive disorder: safety and tolerability associated with dose escalation. Depress Anxiety 2007; 24(1): 41–52PubMedCrossRef Wohlreich MM, Mallinckrodt CH, Prakash A, et al. Duloxetine for the treatment of major depressive disorder: safety and tolerability associated with dose escalation. Depress Anxiety 2007; 24(1): 41–52PubMedCrossRef
89.
Zurück zum Zitat Himmerich H, Fulda S, Schaaf L, et al. Changes in weight and glucose tolerance during treatment with mirtazapine. Diabetes Care 2006 Jan; 29(1): 170PubMedCrossRef Himmerich H, Fulda S, Schaaf L, et al. Changes in weight and glucose tolerance during treatment with mirtazapine. Diabetes Care 2006 Jan; 29(1): 170PubMedCrossRef
90.
Zurück zum Zitat Nicholas LM, Ford AL, Esposito SM, et al. The effects of mirtazapine on plasma lipid profiles in healthy subjects. J Clin Psychiatry 2003 Aug; 64(8): 883–9PubMedCrossRef Nicholas LM, Ford AL, Esposito SM, et al. The effects of mirtazapine on plasma lipid profiles in healthy subjects. J Clin Psychiatry 2003 Aug; 64(8): 883–9PubMedCrossRef
91.
Zurück zum Zitat Laimer M, Kramer-Reinstadler K, Rauchenzauner M, et al. Effect of mirtazapine treatment on body composition and metabolism. J Clin Psychiatry 2006; 67: 421–4PubMedCrossRef Laimer M, Kramer-Reinstadler K, Rauchenzauner M, et al. Effect of mirtazapine treatment on body composition and metabolism. J Clin Psychiatry 2006; 67: 421–4PubMedCrossRef
92.
Zurück zum Zitat Carpenter LL, Jocic Z, Hall JM, et al. Mirtazapine augmentation in the treatment of refractory depression. J Clin Psychiatry 1999 Jan; 60(1): 45–9PubMedCrossRef Carpenter LL, Jocic Z, Hall JM, et al. Mirtazapine augmentation in the treatment of refractory depression. J Clin Psychiatry 1999 Jan; 60(1): 45–9PubMedCrossRef
93.
Zurück zum Zitat Danileviciute V, Sveikata A, Adomaitiene V, et al. Efficacy, tolerability, and preference of mirtazapine orally disintegrating tablets in depressed patients: a 17-week naturalistic study in Lithuania. Medicina (Kaunas) 2009; 45(10): 778–84 Danileviciute V, Sveikata A, Adomaitiene V, et al. Efficacy, tolerability, and preference of mirtazapine orally disintegrating tablets in depressed patients: a 17-week naturalistic study in Lithuania. Medicina (Kaunas) 2009; 45(10): 778–84
94.
Zurück zum Zitat Hennings JM, Ising M, Grautoff S, et al. Glucose tolerance in depressed inpatients, under treatment with mirtazapine and in healthy controls. Exp Clin Endocrinol Diabetes 2010 Feb; 118(2): 98–100PubMedCrossRef Hennings JM, Ising M, Grautoff S, et al. Glucose tolerance in depressed inpatients, under treatment with mirtazapine and in healthy controls. Exp Clin Endocrinol Diabetes 2010 Feb; 118(2): 98–100PubMedCrossRef
95.
Zurück zum Zitat Fisfalen ME, Hsiung RC. Glucose dysregulation and mirtazapine-induced weight gain. Am J Psychiatry 2003 Apr; 160(4): 797PubMedCrossRef Fisfalen ME, Hsiung RC. Glucose dysregulation and mirtazapine-induced weight gain. Am J Psychiatry 2003 Apr; 160(4): 797PubMedCrossRef
96.
Zurück zum Zitat Gadde KM, Parker CB, Maner LG, et al. Bupropion for weight loss: an investigation of efficacy and tolerability in overweight and obese women. Obes Res 2001 Sep; 9(9): 544–51PubMedCrossRef Gadde KM, Parker CB, Maner LG, et al. Bupropion for weight loss: an investigation of efficacy and tolerability in overweight and obese women. Obes Res 2001 Sep; 9(9): 544–51PubMedCrossRef
97.
Zurück zum Zitat Jain AK, Kaplan RA, Gadde KM, et al. Bupropion SR vs. placebo for weight loss in obese patients with depressive symptoms. Obes Res 2002 Oct; 10(10): 1049–56 Jain AK, Kaplan RA, Gadde KM, et al. Bupropion SR vs. placebo for weight loss in obese patients with depressive symptoms. Obes Res 2002 Oct; 10(10): 1049–56
98.
Zurück zum Zitat Croft H, Settle Jr E, Houser T, et al. A placebo-controlled comparison of the antidepressant efficacy and effects on sexual functioning of sustained-release bupropion and sertraline. Clin Ther 1999 Apr; 21(4): 643–58PubMedCrossRef Croft H, Settle Jr E, Houser T, et al. A placebo-controlled comparison of the antidepressant efficacy and effects on sexual functioning of sustained-release bupropion and sertraline. Clin Ther 1999 Apr; 21(4): 643–58PubMedCrossRef
99.
Zurück zum Zitat Feighner J, Hendrickson G, Miller L, et al. Double-blind comparison of doxepin versus bupropion in outpatients with a major depressive disorder. J Clin Psychopharmacol 1986 Feb; 6(1): 27–32PubMedCrossRef Feighner J, Hendrickson G, Miller L, et al. Double-blind comparison of doxepin versus bupropion in outpatients with a major depressive disorder. J Clin Psychopharmacol 1986 Feb; 6(1): 27–32PubMedCrossRef
100.
Zurück zum Zitat Thase ME, Haight BR, Johnson MC, et al. A randomized, double-blind, placebo-controlled study of the effect of sustained-release bupropion on blood pressure in individuals with mild untreated hypertension. J Clin Psychopharmacol 2008 Jun; 28(3): 302–7PubMedCrossRef Thase ME, Haight BR, Johnson MC, et al. A randomized, double-blind, placebo-controlled study of the effect of sustained-release bupropion on blood pressure in individuals with mild untreated hypertension. J Clin Psychopharmacol 2008 Jun; 28(3): 302–7PubMedCrossRef
101.
Zurück zum Zitat Lustman PJ, Williams MM, Sayuk GS, et al. Factors influencing glycemic control in type 2 diabetes during acute-and maintenance-phase treatment of major depressive disorder with bupropion. Diabetes Care 2007 Mar; 30(3): 459–66PubMedCrossRef Lustman PJ, Williams MM, Sayuk GS, et al. Factors influencing glycemic control in type 2 diabetes during acute-and maintenance-phase treatment of major depressive disorder with bupropion. Diabetes Care 2007 Mar; 30(3): 459–66PubMedCrossRef
102.
Zurück zum Zitat Goodnick PJ. Use of antidepressants in treatment of comorbid diabetes mellitus and depression as well as in diabetic neuropathy. Ann Clin Psychiatry 2001 Mar; 13(1): 31–41PubMed Goodnick PJ. Use of antidepressants in treatment of comorbid diabetes mellitus and depression as well as in diabetic neuropathy. Ann Clin Psychiatry 2001 Mar; 13(1): 31–41PubMed
103.
Zurück zum Zitat Lustman PJ, Clouse RE. Treatment of depression in diabetes: impact on mood and medical outcome. J Psychosom Res 2002 Oct; 53(4): 917–24PubMedCrossRef Lustman PJ, Clouse RE. Treatment of depression in diabetes: impact on mood and medical outcome. J Psychosom Res 2002 Oct; 53(4): 917–24PubMedCrossRef
104.
Zurück zum Zitat Lustman PJ, Clouse RE. Depression in diabetes: the chicken or the egg? Psychosom Med 2007 May; 69(4): 297–9PubMedCrossRef Lustman PJ, Clouse RE. Depression in diabetes: the chicken or the egg? Psychosom Med 2007 May; 69(4): 297–9PubMedCrossRef
105.
Zurück zum Zitat McIntyre RS, Konarski JZ, Misener VL, et al. Bipolar disorder and diabetes mellitus: epidemiology, etiology, and treatment implications. Ann Clin Psychiatry 2005 Apr; 17(2): 83–93PubMedCrossRef McIntyre RS, Konarski JZ, Misener VL, et al. Bipolar disorder and diabetes mellitus: epidemiology, etiology, and treatment implications. Ann Clin Psychiatry 2005 Apr; 17(2): 83–93PubMedCrossRef
106.
Zurück zum Zitat Mukherjee S, Decina P, Bocola V, et al. Diabetes mellitus in schizophrenic patients. Compr Psychiatry 1996 Jan; 37(1): 68–73PubMedCrossRef Mukherjee S, Decina P, Bocola V, et al. Diabetes mellitus in schizophrenic patients. Compr Psychiatry 1996 Jan; 37(1): 68–73PubMedCrossRef
107.
Zurück zum Zitat Braceland JF, Meduna LJ, Vaichulis JA. Delayed action of insulin in schizophrenia. Am J Psychiatry 1946; 102: 108–10 Braceland JF, Meduna LJ, Vaichulis JA. Delayed action of insulin in schizophrenia. Am J Psychiatry 1946; 102: 108–10
108.
Zurück zum Zitat Mukherjee S, Schnur DB, Reddy R. Family history of type 2 diabetes in schizophrenic patients. Lancet 1989 Mar 4; 1(8636): 495PubMedCrossRef Mukherjee S, Schnur DB, Reddy R. Family history of type 2 diabetes in schizophrenic patients. Lancet 1989 Mar 4; 1(8636): 495PubMedCrossRef
109.
Zurück zum Zitat Andersohn F, Schade R, Suissa S, et al. Long-term use of antidepressants for depressive disorders and the risk of diabetes mellitus. Am J Psychiatry 2009 May; 166(5): 591–8PubMedCrossRef Andersohn F, Schade R, Suissa S, et al. Long-term use of antidepressants for depressive disorders and the risk of diabetes mellitus. Am J Psychiatry 2009 May; 166(5): 591–8PubMedCrossRef
110.
Zurück zum Zitat Raskin JWFWJFSCCJW. Duloxetine does not affect glycemic control or lipid profiles in patients with diabetic neuropathic pain. Presented at the American Diabetes Association; 2004 Jun 4–8; Orlando (FL) Raskin JWFWJFSCCJW. Duloxetine does not affect glycemic control or lipid profiles in patients with diabetic neuropathic pain. Presented at the American Diabetes Association; 2004 Jun 4–8; Orlando (FL)
111.
Zurück zum Zitat Othmer E, Othmer SC, Stern WC, et al. Long-term efficacy and safety of bupropion. J Clin Psychiatry 1983 May; 44 (5 Pt 2): 153–6PubMed Othmer E, Othmer SC, Stern WC, et al. Long-term efficacy and safety of bupropion. J Clin Psychiatry 1983 May; 44 (5 Pt 2): 153–6PubMed
112.
Zurück zum Zitat Okamura F, Tashiro A, Utumi A, et al. Insulin resistance in patients with depression and its changes during the clinical course of depression: minimal model analysis. Metabolism 2000 Oct; 49(10): 1255–60PubMedCrossRef Okamura F, Tashiro A, Utumi A, et al. Insulin resistance in patients with depression and its changes during the clinical course of depression: minimal model analysis. Metabolism 2000 Oct; 49(10): 1255–60PubMedCrossRef
113.
Zurück zum Zitat Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002 Dec 17; 106 (25): 3143-421 Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002 Dec 17; 106 (25): 3143-421
114.
Zurück zum Zitat Assmann G, Schulte H, Funke H, et al. The emergence of triglycerides as a significant independent risk factor in coronary artery disease. Eur Heart J 1998 Oct; 19 Suppl. M: M8–14PubMed Assmann G, Schulte H, Funke H, et al. The emergence of triglycerides as a significant independent risk factor in coronary artery disease. Eur Heart J 1998 Oct; 19 Suppl. M: M8–14PubMed
115.
Zurück zum Zitat Law MR, Wald NJ, Thompson SG. By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease? BMJ 1994 Feb 5; 308(6925): 367–72PubMedCrossRef Law MR, Wald NJ, Thompson SG. By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease? BMJ 1994 Feb 5; 308(6925): 367–72PubMedCrossRef
116.
Zurück zum Zitat Austin MA, Hokanson JE, Edwards KL. Hypertriglyceridemia as a cardiovascular risk factor. Am J Cardiol 1998 Feb 26; 81(4A): 7B–12BPubMedCrossRef Austin MA, Hokanson JE, Edwards KL. Hypertriglyceridemia as a cardiovascular risk factor. Am J Cardiol 1998 Feb 26; 81(4A): 7B–12BPubMedCrossRef
117.
Zurück zum Zitat Canadian Pharmacist Association. Compendium of pharmaceuticals and specialties. Ottawa (ON): Canadian Pharmacist Association, 2007 Canadian Pharmacist Association. Compendium of pharmaceuticals and specialties. Ottawa (ON): Canadian Pharmacist Association, 2007
118.
Zurück zum Zitat Liebowitz MR, Gelenberg AJ, Munjack D. Venlafaxine extended release vs placebo and paroxetine in social anxiety disorder. Arch Gen Psychiatry 2005 Feb; 62(2): 190–8PubMedCrossRef Liebowitz MR, Gelenberg AJ, Munjack D. Venlafaxine extended release vs placebo and paroxetine in social anxiety disorder. Arch Gen Psychiatry 2005 Feb; 62(2): 190–8PubMedCrossRef
119.
Zurück zum Zitat Visser M, Seidell JC, Koppeschaar HP, et al. No specific effect of fluoxetine treatment on fasting glucose, insulin, lipid levels, and blood pressure in healthy men with abdominal obesity. Obes Res 1994 Mar; 2(2): 152–9PubMedCrossRef Visser M, Seidell JC, Koppeschaar HP, et al. No specific effect of fluoxetine treatment on fasting glucose, insulin, lipid levels, and blood pressure in healthy men with abdominal obesity. Obes Res 1994 Mar; 2(2): 152–9PubMedCrossRef
120.
Zurück zum Zitat Fisar Z, Anders M, Tvrzicka E, et al. Effect of long-term administration of antidepressants on the lipid composition of brain plasma membranes. Gen Physiol Biophys 2005 Jun; 24(2): 221–36PubMed Fisar Z, Anders M, Tvrzicka E, et al. Effect of long-term administration of antidepressants on the lipid composition of brain plasma membranes. Gen Physiol Biophys 2005 Jun; 24(2): 221–36PubMed
121.
Zurück zum Zitat Masuda Y, Ohnuma S, Sugiyama T. Relationship between antidepressants and glycolipids in the forced swimming test in mice. Methods Find Exp Clin Pharmacol 2000 Nov; 22(9): 667–70PubMedCrossRef Masuda Y, Ohnuma S, Sugiyama T. Relationship between antidepressants and glycolipids in the forced swimming test in mice. Methods Find Exp Clin Pharmacol 2000 Nov; 22(9): 667–70PubMedCrossRef
122.
Zurück zum Zitat Davidson KW, Kupfer DJ, Bigger JT, et al. Assessment and treatment of depression in patients with cardiovascular disease: National Heart, Lung, and Blood Institute Working Group Report. Psychosom Med 2006 Sep; 68(5): 645–50PubMedCrossRef Davidson KW, Kupfer DJ, Bigger JT, et al. Assessment and treatment of depression in patients with cardiovascular disease: National Heart, Lung, and Blood Institute Working Group Report. Psychosom Med 2006 Sep; 68(5): 645–50PubMedCrossRef
123.
Zurück zum Zitat Frasure-Smith N, Lesperance F. Recent evidence linking coronary heart disease and depression. Can J Psychiatry 2006 Oct; 51(12): 730–7PubMed Frasure-Smith N, Lesperance F. Recent evidence linking coronary heart disease and depression. Can J Psychiatry 2006 Oct; 51(12): 730–7PubMed
124.
Zurück zum Zitat Glassman AH, Shapiro PA. Depression and the course of coronary artery disease. Am J Psychiatry 1998 Jan; 155(1): 4–11PubMed Glassman AH, Shapiro PA. Depression and the course of coronary artery disease. Am J Psychiatry 1998 Jan; 155(1): 4–11PubMed
125.
Zurück zum Zitat Dobbels F, De GS, Vanhees L, et al. Depression and the heart: a systematic overview of definition, measurement, consequences and treatment of depression in cardiovascular disease. Eur J Cardiovasc Nurs 2002 Feb; 1(1): 45–55PubMedCrossRef Dobbels F, De GS, Vanhees L, et al. Depression and the heart: a systematic overview of definition, measurement, consequences and treatment of depression in cardiovascular disease. Eur J Cardiovasc Nurs 2002 Feb; 1(1): 45–55PubMedCrossRef
126.
Zurück zum Zitat Kronfol Z. Immune dysregulation in major depression: a critical review of existing evidence. Int J Neuropsychopharmacol 2002 Dec; 5(4): 333–43PubMedCrossRef Kronfol Z. Immune dysregulation in major depression: a critical review of existing evidence. Int J Neuropsychopharmacol 2002 Dec; 5(4): 333–43PubMedCrossRef
127.
Zurück zum Zitat Musselman DL, Evans DL, Nemeroff CB. The relationship of depression to cardiovascular disease: epidemiology, biology, and treatment. Arch Gen Psychiatry 1998 Jul; 55(7): 580–92PubMedCrossRef Musselman DL, Evans DL, Nemeroff CB. The relationship of depression to cardiovascular disease: epidemiology, biology, and treatment. Arch Gen Psychiatry 1998 Jul; 55(7): 580–92PubMedCrossRef
128.
Zurück zum Zitat Panagiotakos DB, Pitsavos C, Chrysohoou C, et al. Inflammation, coagulation, and depressive symptomatology in cardiovascular disease-free people; the ATTICA study. Eur Heart J 2004 Mar; 25(6): 492–9PubMedCrossRef Panagiotakos DB, Pitsavos C, Chrysohoou C, et al. Inflammation, coagulation, and depressive symptomatology in cardiovascular disease-free people; the ATTICA study. Eur Heart J 2004 Mar; 25(6): 492–9PubMedCrossRef
129.
Zurück zum Zitat Ramasubbu R. Insulin resistance: a metabolic link between depressive disorder and atherosclerotic vascular diseases. Med Hypotheses 2002 Nov; 59(5): 537–51PubMedCrossRef Ramasubbu R. Insulin resistance: a metabolic link between depressive disorder and atherosclerotic vascular diseases. Med Hypotheses 2002 Nov; 59(5): 537–51PubMedCrossRef
130.
Zurück zum Zitat Scalco AZ, Scalco MZ, Azul JB, et al. Hypertension and depression. Clinics 2005 Jun; 60(3): 241–50PubMedCrossRef Scalco AZ, Scalco MZ, Azul JB, et al. Hypertension and depression. Clinics 2005 Jun; 60(3): 241–50PubMedCrossRef
131.
Zurück zum Zitat Davidson K, Jonas BS, Dixon KE, et al. Do depression symptoms predict early hypertension incidence in young adults in the CARDIA study? Coronary Artery Risk Development in Young Adults. Arch Intern Med 2000 May 22; 160(10): 1495–500PubMedCrossRef Davidson K, Jonas BS, Dixon KE, et al. Do depression symptoms predict early hypertension incidence in young adults in the CARDIA study? Coronary Artery Risk Development in Young Adults. Arch Intern Med 2000 May 22; 160(10): 1495–500PubMedCrossRef
132.
Zurück zum Zitat Raskin J, Smith TR, Wong K, et al. Duloxetine versus routine care in the long-term management of diabetic peripheral neuropathic pain. J Palliat Med 2006 Feb; 9(1): 29–40PubMedCrossRef Raskin J, Smith TR, Wong K, et al. Duloxetine versus routine care in the long-term management of diabetic peripheral neuropathic pain. J Palliat Med 2006 Feb; 9(1): 29–40PubMedCrossRef
133.
Zurück zum Zitat Wohlreich MM, Perahia DG, Acharya N, et al. Duloxetine hepatic effects: 2006 review. Austria European Congress of Neuropsychopharmacology; 2007 Oct 13; Vienna Wohlreich MM, Perahia DG, Acharya N, et al. Duloxetine hepatic effects: 2006 review. Austria European Congress of Neuropsychopharmacology; 2007 Oct 13; Vienna
134.
Zurück zum Zitat Wilens TE, Hammerness PG, Biederman J, et al. Blood pressure changes associated with medication treatment of adults with attention-deficit/hyperactivity disorder. J Clin Psychiatry 2005 Feb; 66(2): 253–9PubMedCrossRef Wilens TE, Hammerness PG, Biederman J, et al. Blood pressure changes associated with medication treatment of adults with attention-deficit/hyperactivity disorder. J Clin Psychiatry 2005 Feb; 66(2): 253–9PubMedCrossRef
135.
Zurück zum Zitat Roose SP, Dalack GW, Glassman AH, et al. Cardiovascular effects of bupropion in depressed patients with heart disease. Am J Psychiatry 1991 Apr; 148(4): 512–6PubMed Roose SP, Dalack GW, Glassman AH, et al. Cardiovascular effects of bupropion in depressed patients with heart disease. Am J Psychiatry 1991 Apr; 148(4): 512–6PubMed
136.
Zurück zum Zitat Kennedy SH, Lam RW, Cohen NL, et al. Clinical guidelines for the treatment of depressive disorders: IV. Medications and other biological treatments. Can J Psychiatry 2001 Jun; 46 Suppl. 1: 38S–58SPubMed Kennedy SH, Lam RW, Cohen NL, et al. Clinical guidelines for the treatment of depressive disorders: IV. Medications and other biological treatments. Can J Psychiatry 2001 Jun; 46 Suppl. 1: 38S–58SPubMed
137.
Zurück zum Zitat Botella-Carretero JI, Escobar-Morreale HF, Martin I, et al. Weight gain and cardiovascular risk factors during smoking cessation with bupropion or nicotine. Horm Metab Res 2004 Mar; 36(3): 178–82PubMedCrossRef Botella-Carretero JI, Escobar-Morreale HF, Martin I, et al. Weight gain and cardiovascular risk factors during smoking cessation with bupropion or nicotine. Horm Metab Res 2004 Mar; 36(3): 178–82PubMedCrossRef
138.
Zurück zum Zitat Gardner DM, Shulman KI, Walker SE, et al. The making of a user friendly MAOI diet. J Clin Psychiatry 1996 Mar; 57(3): 99–104PubMed Gardner DM, Shulman KI, Walker SE, et al. The making of a user friendly MAOI diet. J Clin Psychiatry 1996 Mar; 57(3): 99–104PubMed
139.
Zurück zum Zitat McElroy SL, Kotwal R, Malhotra S, et al. Are mood disorders and obesity related? A review for the mental health professional. J Clin Psychiatry 2004 May; 65(5): 634–51, quizPubMedCrossRef McElroy SL, Kotwal R, Malhotra S, et al. Are mood disorders and obesity related? A review for the mental health professional. J Clin Psychiatry 2004 May; 65(5): 634–51, quizPubMedCrossRef
140.
Zurück zum Zitat Pine DS, Goldstein RB, Wolk S, et al. The association between childhood depression and adulthood body mass index. Pediatrics 2001 May; 107(5): 1049–56PubMedCrossRef Pine DS, Goldstein RB, Wolk S, et al. The association between childhood depression and adulthood body mass index. Pediatrics 2001 May; 107(5): 1049–56PubMedCrossRef
141.
Zurück zum Zitat McIntyre RS, Konarski JZ, Yatham LN. Comorbidity in bipolar disorder: a framework for rational treatment selection. Hum Psychopharmacol 2004; 19(6): 369–86PubMedCrossRef McIntyre RS, Konarski JZ, Yatham LN. Comorbidity in bipolar disorder: a framework for rational treatment selection. Hum Psychopharmacol 2004; 19(6): 369–86PubMedCrossRef
142.
Zurück zum Zitat Despres JP, Lemieux I, Prud’homme D. Treatment of obesity: need to focus on high risk abdominally obese patients. BMJ 2001 Mar 24; 322(7288): 716–20PubMedCrossRef Despres JP, Lemieux I, Prud’homme D. Treatment of obesity: need to focus on high risk abdominally obese patients. BMJ 2001 Mar 24; 322(7288): 716–20PubMedCrossRef
143.
Zurück zum Zitat Weber-Hamann B, Hentschel F, Kniest A, et al. Hyper-cortisolemic depression is associated with increased intra-abdominal fat. Psychosom Med 2002 Mar; 64(2): 274–7PubMed Weber-Hamann B, Hentschel F, Kniest A, et al. Hyper-cortisolemic depression is associated with increased intra-abdominal fat. Psychosom Med 2002 Mar; 64(2): 274–7PubMed
144.
Zurück zum Zitat Hach I, Ruhl UE, Klotsche J, et al. Associations between waist circumference and depressive disorders. J Affect Disord 2006 Jun; 92(2–3): 305–8PubMedCrossRef Hach I, Ruhl UE, Klotsche J, et al. Associations between waist circumference and depressive disorders. J Affect Disord 2006 Jun; 92(2–3): 305–8PubMedCrossRef
145.
Zurück zum Zitat McIntyre RS, Konarski JZ, Wilkins K, et al. Obesity in bipolar disorder and major depressive disorder: results from a national community health survey on mental health and well-being. Can J Psychiatry 2006; 51: 274–80PubMed McIntyre RS, Konarski JZ, Wilkins K, et al. Obesity in bipolar disorder and major depressive disorder: results from a national community health survey on mental health and well-being. Can J Psychiatry 2006; 51: 274–80PubMed
146.
Zurück zum Zitat Fava M. Weight gain and antidepressants. J Clin Psychiatry 2000; 61 Suppl. 11: 37–41 Fava M. Weight gain and antidepressants. J Clin Psychiatry 2000; 61 Suppl. 11: 37–41
147.
Zurück zum Zitat Balon R, Yeragani VK, Pohl R, et al. Changes in appetite and weight during the pharmacological treatment of patients with panic disorder. Can J Psychiatry 1993 Feb; 38(1): 19–22PubMed Balon R, Yeragani VK, Pohl R, et al. Changes in appetite and weight during the pharmacological treatment of patients with panic disorder. Can J Psychiatry 1993 Feb; 38(1): 19–22PubMed
148.
Zurück zum Zitat Bradwejn J, Ahokas A, Stein DJ, et al. Venlafaxine extended-release capsules in panic disorder: flexible-dose, double-blind, placebo-controlled study. Br J Psychiatry 2005 Oct; 187: 352–9PubMedCrossRef Bradwejn J, Ahokas A, Stein DJ, et al. Venlafaxine extended-release capsules in panic disorder: flexible-dose, double-blind, placebo-controlled study. Br J Psychiatry 2005 Oct; 187: 352–9PubMedCrossRef
149.
Zurück zum Zitat Feiger AD, Bielski RJ, Bremner J, et al. Double-blind, placebo-substitution study of nefazodone in the prevention of relapse during continuation treatment of outpatients with major depression. Int Clin Psychopharmacol 1999 Jan; 14(1): 19–28PubMedCrossRef Feiger AD, Bielski RJ, Bremner J, et al. Double-blind, placebo-substitution study of nefazodone in the prevention of relapse during continuation treatment of outpatients with major depression. Int Clin Psychopharmacol 1999 Jan; 14(1): 19–28PubMedCrossRef
150.
Zurück zum Zitat Frank E, Kupfer DJ, Bulik CM, et al. Imipramine and weight gain during the treatment of recurrent depression. J Affect Disord 1990 Nov; 20(3): 165–72PubMedCrossRef Frank E, Kupfer DJ, Bulik CM, et al. Imipramine and weight gain during the treatment of recurrent depression. J Affect Disord 1990 Nov; 20(3): 165–72PubMedCrossRef
151.
Zurück zum Zitat Silverstone PH, Ravindran A. Once-daily venlafaxine extended release (XR) compared with fluoxetine in outpatients with depression and anxiety: Venlafaxine XR 360 Study Group. J Clin Psychiatry 1999 Jan; 60(1): 22–8PubMedCrossRef Silverstone PH, Ravindran A. Once-daily venlafaxine extended release (XR) compared with fluoxetine in outpatients with depression and anxiety: Venlafaxine XR 360 Study Group. J Clin Psychiatry 1999 Jan; 60(1): 22–8PubMedCrossRef
152.
Zurück zum Zitat Garland EJ, Remick RA, Zis AP. Weight gain with antidepressants and lithium. J Clin Psychopharmacol 1988 Oct; 8(5): 323–30PubMedCrossRef Garland EJ, Remick RA, Zis AP. Weight gain with antidepressants and lithium. J Clin Psychopharmacol 1988 Oct; 8(5): 323–30PubMedCrossRef
153.
Zurück zum Zitat Kazes M, Danion JM, Grange D, et al. Eating behaviour and depression before and after antidepressant treatment: a prospective, naturalistic study. J Affect Disord 1994 Mar; 30(3): 193–207PubMedCrossRef Kazes M, Danion JM, Grange D, et al. Eating behaviour and depression before and after antidepressant treatment: a prospective, naturalistic study. J Affect Disord 1994 Mar; 30(3): 193–207PubMedCrossRef
154.
Zurück zum Zitat Zimmermann U, Kraus T, Himmerich H, et al. Epidemiology, implications and mechanisms underlying drug-induced weight gain in psychiatric patients. J Psychiatr Res 2003 May; 37(3): 193–220PubMedCrossRef Zimmermann U, Kraus T, Himmerich H, et al. Epidemiology, implications and mechanisms underlying drug-induced weight gain in psychiatric patients. J Psychiatr Res 2003 May; 37(3): 193–220PubMedCrossRef
155.
Zurück zum Zitat Huang TL, Lin FC. High-sensitivity C-reactive protein levels in patients with major depressive disorder and bipolar mania. Prog Neuropsychopharmacol Biol Psychiatry 2007 Mar 30; 31(2): 370–2PubMedCrossRef Huang TL, Lin FC. High-sensitivity C-reactive protein levels in patients with major depressive disorder and bipolar mania. Prog Neuropsychopharmacol Biol Psychiatry 2007 Mar 30; 31(2): 370–2PubMedCrossRef
156.
Zurück zum Zitat Kendall-Tackett KA. Inflammation, cardiovascular disease, and metabolic syndrome as sequelae of violence against women: the role of depression, hostility, and sleep disturbance. Trauma Violence Abuse 2007 Apr; 8(2): 117–26PubMedCrossRef Kendall-Tackett KA. Inflammation, cardiovascular disease, and metabolic syndrome as sequelae of violence against women: the role of depression, hostility, and sleep disturbance. Trauma Violence Abuse 2007 Apr; 8(2): 117–26PubMedCrossRef
157.
Zurück zum Zitat Kiecolt-Glaser JK, Glaser R. Depression and immune function: central pathways to morbidity and mortality. J Psychosom Res 2002 Oct; 53(4): 873–6PubMedCrossRef Kiecolt-Glaser JK, Glaser R. Depression and immune function: central pathways to morbidity and mortality. J Psychosom Res 2002 Oct; 53(4): 873–6PubMedCrossRef
158.
Zurück zum Zitat Licinio J, Wong ML. The role of inflammatory mediators in the biology of major depression: central nervous system cytokines modulate the biological substrate of depressive symptoms, regulate stress-responsive systems, and contribute to neurotoxicity and neuroprotection. Mol Psychiatry 1999 Jul; 4(4): 317–27PubMedCrossRef Licinio J, Wong ML. The role of inflammatory mediators in the biology of major depression: central nervous system cytokines modulate the biological substrate of depressive symptoms, regulate stress-responsive systems, and contribute to neurotoxicity and neuroprotection. Mol Psychiatry 1999 Jul; 4(4): 317–27PubMedCrossRef
159.
Zurück zum Zitat Capuron L, Gumnick JF, Musselman DL, et al. Neurobehavioral effects of interferon-alpha in cancer patients: phenomenology and paroxetine responsiveness of symptom dimensions. Neuropsychopharmacology 2002 May; 26(5): 643–52PubMedCrossRef Capuron L, Gumnick JF, Musselman DL, et al. Neurobehavioral effects of interferon-alpha in cancer patients: phenomenology and paroxetine responsiveness of symptom dimensions. Neuropsychopharmacology 2002 May; 26(5): 643–52PubMedCrossRef
160.
Zurück zum Zitat Capuron L, Miller AH. Cytokines and psychopathology: lessons from interferon-alpha. Biol Psychiatry 2004 Dec 1; 56(11): 819–24PubMedCrossRef Capuron L, Miller AH. Cytokines and psychopathology: lessons from interferon-alpha. Biol Psychiatry 2004 Dec 1; 56(11): 819–24PubMedCrossRef
161.
Zurück zum Zitat Khanzode SD, Dakhale GN, Khanzode SS, et al. Oxidative damage and major depression: the potential antioxidant action of selective serotonin re-uptake inhibitors. Redox Rep 2003; 8(6): 365–70PubMedCrossRef Khanzode SD, Dakhale GN, Khanzode SS, et al. Oxidative damage and major depression: the potential antioxidant action of selective serotonin re-uptake inhibitors. Redox Rep 2003; 8(6): 365–70PubMedCrossRef
162.
Zurück zum Zitat McEwen BS, Magarinos AM, Reagan LP. Studies of hormone action in the hippocampal formation: possible relevance to depression and diabetes. J Psychosom Res 2002 Oct; 53(4): 883–90PubMedCrossRef McEwen BS, Magarinos AM, Reagan LP. Studies of hormone action in the hippocampal formation: possible relevance to depression and diabetes. J Psychosom Res 2002 Oct; 53(4): 883–90PubMedCrossRef
163.
Zurück zum Zitat Andrews RC, Walker BR. Glucocorticoids and insulin resistance: old hormones, new targets. Clin Sci (Lond) 1999 May; 96(5): 513–23CrossRef Andrews RC, Walker BR. Glucocorticoids and insulin resistance: old hormones, new targets. Clin Sci (Lond) 1999 May; 96(5): 513–23CrossRef
164.
Zurück zum Zitat McEwen BS, Stellar E. Stress and the individual: mechanisms leading to disease. Arch Intern Med 1993 Sep 27; 153(18): 2093–101PubMedCrossRef McEwen BS, Stellar E. Stress and the individual: mechanisms leading to disease. Arch Intern Med 1993 Sep 27; 153(18): 2093–101PubMedCrossRef
165.
166.
Zurück zum Zitat Axelson DA, Doraiswamy PM, McDonald WM, et al. Hypercortisolemia and hippocampal changes in depression. Psychiatry Res 1993 May; 47(2): 163–73PubMedCrossRef Axelson DA, Doraiswamy PM, McDonald WM, et al. Hypercortisolemia and hippocampal changes in depression. Psychiatry Res 1993 May; 47(2): 163–73PubMedCrossRef
167.
Zurück zum Zitat Belanoff JK, Kalehzan M, Sund B, et al. Cortisol activity and cognitive changes in psychotic major depression. Am J Psychiatry 2001 Oct; 158(10): 1612–6PubMedCrossRef Belanoff JK, Kalehzan M, Sund B, et al. Cortisol activity and cognitive changes in psychotic major depression. Am J Psychiatry 2001 Oct; 158(10): 1612–6PubMedCrossRef
168.
Zurück zum Zitat Keller J, Flores B, Gomez RG, et al. Cortisol circadian rhythm alterations in psychotic major depression. Biol Psychiatry 2006 Aug 1; 60(3): 275–81PubMedCrossRef Keller J, Flores B, Gomez RG, et al. Cortisol circadian rhythm alterations in psychotic major depression. Biol Psychiatry 2006 Aug 1; 60(3): 275–81PubMedCrossRef
169.
Zurück zum Zitat Rebuffe-Scrive M, Walsh UA, McEwen B, et al. Effect of chronic stress and exogenous glucocorticoids on regional fat distribution and metabolism. Physiol Behav 1992 Sep; 52(3): 583–90PubMedCrossRef Rebuffe-Scrive M, Walsh UA, McEwen B, et al. Effect of chronic stress and exogenous glucocorticoids on regional fat distribution and metabolism. Physiol Behav 1992 Sep; 52(3): 583–90PubMedCrossRef
170.
Zurück zum Zitat Gil K, Radzillowicz P, Zdrojewski T, et al. Relationship between the prevalence of depressive symptoms and metabolic syndrome: results of the SOPKARD Project. Kardiol Pol 2006 May; 64(5): 464–9PubMed Gil K, Radzillowicz P, Zdrojewski T, et al. Relationship between the prevalence of depressive symptoms and metabolic syndrome: results of the SOPKARD Project. Kardiol Pol 2006 May; 64(5): 464–9PubMed
171.
Zurück zum Zitat Kinder LS, Carnethon MR, Palaniappan LP, et al. Depression and the metabolic syndrome in young adults: findings from the Third National Health and Nutrition Examination Survey. Psychosom Med 2004 May; 66(3): 316–22PubMedCrossRef Kinder LS, Carnethon MR, Palaniappan LP, et al. Depression and the metabolic syndrome in young adults: findings from the Third National Health and Nutrition Examination Survey. Psychosom Med 2004 May; 66(3): 316–22PubMedCrossRef
172.
Zurück zum Zitat Vaccarino V, McClure C, Johnson BD, et al. Depression, the metabolic syndrome and cardiovascular risk. Psychosom Med 2008 Jan; 70(1): 40–8PubMedCrossRef Vaccarino V, McClure C, Johnson BD, et al. Depression, the metabolic syndrome and cardiovascular risk. Psychosom Med 2008 Jan; 70(1): 40–8PubMedCrossRef
173.
Zurück zum Zitat Angst F, Stassen HH, Clayton PJ, et al. Mortality of patients with mood disorders: follow-up over 34–38 years. J Affect Disord 2002 Apr; 68(2–3): 167–81PubMedCrossRef Angst F, Stassen HH, Clayton PJ, et al. Mortality of patients with mood disorders: follow-up over 34–38 years. J Affect Disord 2002 Apr; 68(2–3): 167–81PubMedCrossRef
174.
Zurück zum Zitat Osby U, Brandt L, Correia N, et al. Excess mortality in bipolar and unipolar disorder in Sweden. Arch Gen Psychiatry 2001 Sep; 58(9): 844–50PubMedCrossRef Osby U, Brandt L, Correia N, et al. Excess mortality in bipolar and unipolar disorder in Sweden. Arch Gen Psychiatry 2001 Sep; 58(9): 844–50PubMedCrossRef
175.
Zurück zum Zitat Enns MW, Swenson JR, McIntyre RS, et al. Clinical guidelines for the treatment of depressive disorders: VII. Comorbidity. Can J Psychiatry 2001 Jun; 46 Suppl. 1: 77S–90SPubMed Enns MW, Swenson JR, McIntyre RS, et al. Clinical guidelines for the treatment of depressive disorders: VII. Comorbidity. Can J Psychiatry 2001 Jun; 46 Suppl. 1: 77S–90SPubMed
176.
Zurück zum Zitat Glassman AH, O’Connor CM, Califf RM, et al. Sertraline treatment of major depression in patients with acute MI or unstable angina. JAMA 2002 Aug 14; 288(6): 701–9PubMedCrossRef Glassman AH, O’Connor CM, Califf RM, et al. Sertraline treatment of major depression in patients with acute MI or unstable angina. JAMA 2002 Aug 14; 288(6): 701–9PubMedCrossRef
177.
Zurück zum Zitat American Diabetes Association. Screening for type 2 diabetes. Diabetes Care 2004 Jan; 27 Suppl. 1: S11–4CrossRef American Diabetes Association. Screening for type 2 diabetes. Diabetes Care 2004 Jan; 27 Suppl. 1: S11–4CrossRef
178.
Zurück zum Zitat McIntyre RS. Overview of managing medical comorbidities in patients with severe mental illness. J Clin Psychiatry 2009 Jun; 70(6): e17PubMedCrossRef McIntyre RS. Overview of managing medical comorbidities in patients with severe mental illness. J Clin Psychiatry 2009 Jun; 70(6): e17PubMedCrossRef
Metadaten
Titel
The Association between Conventional Antidepressants and the Metabolic Syndrome
A Review of the Evidence and Clinical Implications
verfasst von
Dr Roger S. McIntyre
Ka Young Park
Candy W. Y. Law
Farah Sultan
Amanda Adams
Maria Teresa Lourenco
Aaron K. S. Lo
Joanna K. Soczynska
Hanna Woldeyohannes
Mohammad Alsuwaidan
Jinju Yoon
Sidney H. Kennedy
Publikationsdatum
01.09.2010
Verlag
Springer International Publishing
Erschienen in
CNS Drugs / Ausgabe 9/2010
Print ISSN: 1172-7047
Elektronische ISSN: 1179-1934
DOI
https://doi.org/10.2165/11533280-000000000-00000

Weitere Artikel der Ausgabe 9/2010

CNS Drugs 9/2010 Zur Ausgabe

Correspondence

The Author’s Reply

Adis Drug Evaluation

Escitalopram

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.